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Abstract
Background:  Migration is one of the major causes of tuberculosis in developed countries.
Undocumented patients are usually not screened at the border and are not covered by a health
insurance increasing their risk of developing the disease unnoticed. Urban health centres could help
identify this population at risk. The objective of this study is to assess the prevalence of latent
tuberculosis infection (LTBI) and adherence to preventive treatment in a population of
undocumented immigrant patients.
Methods: All consecutive undocumented patients that visited two urban healthcare centres for
vulnerable populations in Lausanne, Switzerland for the first time were offered tuberculosis
screening with an interferon-γ assay. Preventive treatment was offered if indicated. Adherence to
treatment was evaluated monthly over a nine month period.
Results:  Of the 161 participants, 131 (81.4%) agreed to screening and 125 had complete
examinations. Twenty-four of the 125 patients (19.2%; CI95% 12.7;27.2) had positive interferon-γ
assay results, two of which had active tuberculosis. Only five patients with LTBI completed full
preventive treatments. Five others initiated the treatment but did not follow through.
Conclusion: Screening for tuberculosis infection in this hard-to-reach population is feasible in
dedicated urban clinics, and the prevalence of LTBI is high in this vulnerable population. However,
the low adherence to treatment is an important public health concern, and new strategies are
needed to address this problem.
Background
Each year, more than 8 million people develop active
tuberculosis (TB) worldwide with regional variability. It is
the most common cause of death from communicable
diseases [1,2]. Movement of people between countries has
a large influence on the incidence of TB in Western-
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Europe [3-5]. Several studies have shown that most
reported cases are due to reactivation of infections
acquired abroad but that transmission to other people in
the host country is rare [6-9]. Therefore, screening for
tuberculosis among immigrants is performed in many
developed countries with the aim of detecting and treating
the active disease [10,11] or a latent tuberculosis infection
(LTBI) [12-14]. The introduction of interferon-γ assays has
improved specificity for detecting LTBI compared with the
tuberculin skin test [15,16]. This promises a considerable
improvement in the cost-effectiveness of targeted screen-
ing programs [17-20]. However, there is no clear consen-
sus regarding the true benefits of screening and it is
difficult to assess treatment policies [21].
In practice, screening policies address immigrants that
enter into the country via an official channel (asylum
claim & working permit). In Switzerland, a screening pol-
icy exists for asylum seekers and refugees at the border,
but no system exists for undocumented immigrants from
countries with a high prevalence of tuberculosis [22,23].
The latter represent a large proportion of the foreign-born
population (estimates vary between 150,000 and 300,000
people for a total immigrant population of 7.5 million)
[24]. Targeted screening programs may be cost-effective
[25], but further studies are needed to evaluate the preva-
lence of LTBI, the acceptability of screening, and adher-
ence to treatment in this hard-to-reach vulnerable
population.
Methods
We conducted a pilot trial to investigate the acceptance,
prevalence of positive findings, and adherence to treat-
ment of undocumented immigrant patients offered LTBI
screening. We offered a free tuberculosis screening proce-
dure to all consecutive, undocumented immigrants that
were over 15 years old, had no major psychiatric disabili-
ties, and were visiting one of two low-threshold health-
care premises for the first time in Lausanne. The recruit-
ment proceeded during a six-month period in 2007 at the
Department of Ambulatory Care and Community Medi-
cine of the University Hospital and at the Point d'Eau,
Vulnerable population urban healthcare centre. Patients
were evaluated by nurse practitioners or primary care phy-
sicians trained in community medicine.
Patients were asked to answer a health questionnaire in
their preferred language that highlighted symptoms or
history that might be associated with tuberculosis (cough,
sputum, night sweating, weight loss, prior contact with
tuberculosis, prior treatment for tuberculosis, and smok-
ing). From each patient, 8 ml of blood was collected in a
Vacutainer-CPT. Within the next 24 h, an enzyme-linked
immunospot  γ-interferon assay (T-Spot.TB™, Oxford
Immunotec) was performed to assess the previous tuber-
culosis infection status. This test has been shown to have
a sensitivity of 90% and a specificity of 93% to detect
latent tuberculosis [26]. If results were inconclusive, the
assay was repeated. Patients with suspect symptoms, a
prior history of tuberculosis, prior contact with tuberculo-
sis, or a positive interferon-γ test result had a chest X-ray
and a medical examination by a physician. A bacteriolog-
ical examination of sputum was performed in all patients
that had suspected symptoms or an abnormal X-ray.
Patients with active tuberculosis were treated in our
Department according to the current Swiss Guidelines
[27,28]. Patients that had a positive interferon-γ assay
with no signs of tuberculosis were offered preventive treat-
ment. Treated patients were followed for a six-month
period. We monitored the acceptance of screening, the
number of patients that returned for test results, the
number of patients that accepted treatment, and the
number of patients that finished treatment.
Sample size was calculated to assure a 0.1 margin of error
for the LTBI prevalence rate with a significant level set at
95% and an expected prevalence of 0.5 (worse case sce-
nario). We estimated that 97 patients were necessary to
sufficiently power the analysis. In anticipation of loss to
follow-up and missing data, we included 130 participants
in the study. Prevalence and acceptance rates are given
with a 95% confidence interval. Other results are given in
a descriptive form without inference, as we expected small
sample sizes.
All patients provided written informed consent for partic-
ipation, the protocol was approved by the Lausanne Uni-
versity Ethical Committee (protocol 183/06), and the
study conformed to the standards defined in the Declara-
tion of Helsinki.
Results
Between January and July 2007, 161 undocumented
immigrants that visited one of two medical centres for the
first time were asked to participate in this study. Among
these, 131 agreed to answer a questionnaire regarding
symptoms and history associated with tuberculosis and
had a blood sample drawn for an interferon-γ assay. The
questionnaire acceptance rate was 81.4% (CI95%
74.5;87.1). However, of these 131 patients, two patients
left the waiting room before seeing the practitioner, and
one refused to give a blood sample. Thus, 128 laboratory
samples were tested, and five of these were inconclusive.
Twenty-five patients (19.5%) did not return for their test
results, and three of these had an initial inconclusive lab-
oratory result. Confirmation of the inconclusive essay
revealed on positive and one negative patient. Laboratory
results were therefore available for 125 patients (Figure 1).BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34
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Flow-chart of patient inclusion in the study Figure 1
Flow-chart of patient inclusion in the study.
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The demographic data are given in Table 1. The mean age
of the participants was 34.8 years, 47.2% were female, and
64% were single. Most of the patients (83.2%) entered
Switzerland without receiving the official tuberculosis
screening procedure for asylum seekers. The majority of
patients were undocumented immigrants born in Latin
America (51.2%), and many were from Sub-Saharan
Africa (19.2%). Most of the patients (76.8%) were from
countries that had a high incidence rate of active tubercu-
losis (≥ 50/100,000 per year). The mean length of time
spent in Switzerland was under two years for 52.8% of the
population. Only five out of the 24 participants that tested
positive and 15 of the 101 participants that tested negative
for TB reported previous contact with a person that had TB
Thus, the sensitivity of this question was 20.8% and the
specificity was 85.1%.
The interferon-γ assay indicated that 24 immigrants were
positive for TB (19.2%) [CI 95% 12.7–27.2]. Of these,
two had smear-positive tuberculosis (1.6%) [CI95% 0.2–
5.7], three had a history of prior treatment for tuberculo-
sis, one had a history of prior treatment for LTBI, and 18
had no active or prior tuberculosis (14.4%, CI95% 8.8–
21.8). One patient was suspected to falsely have a negative
Table 1: Population characteristics
Population characteristic Interferon-γ assay Total
Positive
n = 24
n (%)
Negative
n = 101
n (%)
n = 125
n (%)
Age
<20 0 (0) 3 (3.0) 3 (2.4)
20–39 13 (54) 78 (77) 91 (72.8)
40–59 11 (46) 18 (18)) 29 (23.2)
60 or more 0 (0) 2 (2) 2 (1.6)
Gender
Male 13 (54) 53 (52) 66 (52.8)
Level of education
Compulsory or less 11 (46) 46 (46) 55 (45.6)
Reasons for migrating
Economical 16 (64) 63 (63) 79 (63.2)
Political persecution 2 (8) 19 (19) 21 (16.8)
Religious persecution 1 (4) 2 (2) 3 (2.4)
Disease 4 (17) 2 (2) 6 (4.8)
Family grouping 4 (17) 16 (16) 20 (16)
Studies 2 (8) 8 (8) 10 (8.0)
Other 1 (4) 6 (6) 7 (5.6)
Arrived in Switzerland
Less than 2 years 12 (48) 54 (54) 66 (52.8)
2–7 years 6 (25) 38 (38) 44 (35.2)
More than 7 years 6 (24) 9 (9) 15 (12.0)
Tobacco
Smoker 9 (37) 39 (39) 48 (38.4)
Close contact with TBC
Reported 5 (21) 15 (15) 20 (16.0)
Not reported 19 (79) 86 (85) 20 (84.0)
Proximity of at least one hour with someone during previous 3 months
Disco or dancing 8 (33) 43 (43) 51 (40.8)
Religious meetings 10 (42) 41 (41) 51 (40.8)
Interior sports 1 (4) 22 (22) 23 (18.4)
Restaurants or pubs 4 (17) 16 (16) 20 (16)
Welfare hostel 1 (4) 5 (4) 6 (4.8)
Other 1 (4) 8 (8) 9 (7.2)BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34
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interferon-γ assays as he had been treated for a sputum
confirmed active tuberculosis two years previously.
The two patients with active tuberculosis were isolated
and treated according to the current Swiss Guidelines
[27]. Both were adherent to treatment and were cured.
Among the 14 immigrants with no prior history of TB and
a positive interferon-γ assay result, four had counter-indi-
cations for preventive treatment (high age, liver disease),
four did not show up for further examinations, and 10
accepted preventive treatment for LTBI. Of the 10 that
accepted preventative treatment, only five followed the
treatment until the scheduled completion. Therefore, full
treatment was sustained by 5/18 patients with LTBI (Fig-
ure 2).
Discussion
In our study, 19.2% (24/125) of the undocumented
immigrant patients had positive interferon-γ assay results
and 14.4% (18/125) had LTBI that was previously unde-
tected. Carvalho et al [25] found similar results (15%; 15/
100) for undocumented immigrant patients attending an
Italian health care service. Although the sample sizes were
small in both these studies, the observed prevalence of
positive interferon-γ results appeared to be substantial
compared to other population groups, including: German
subjects that had been in close contact with an index case
(10%) [29], healthcare workers in Denmark (1.4%)[30]
or Japan (9.9%)[31], American Navy recruits (0.6%)[32],
and the general Japanese population (7.1%)[33]. Prior
exposure to an index case with pulmonary TB in the coun-
try of origin appeared to be the primary cause of LTBI in
low-incidence rate countries [3]. Furthermore, the risk of
reactivating a LTBI into active tuberculosis seemed to
mainly be related to the initial exposure in high incidence
countries of origin and not to other risk behaviours or
environmental conditions in the host country [7,34].
More than 3/4 of undocumented immigrants consulting
healthcare centres in Western Switzerland are from coun-
tries with incidence rates of tuberculosis above 50 cases/
100,000 people per year. This is most likely the major rea-
son for the high prevalence of LTBI in this population.
Targeted tuberculosis screening seems to be more cost-
effective for preventing outbreaks than systematic screen-
ing [17,21]. Clinical trials have shown that preventive
treatment reduced infection rates by more than half when
strict adherence was achieved [14,35]. Most cost-effective-
ness studies [18-20,36,37] are based on estimates that do
not take into consideration the number of positive inter-
feron-γ assays that are due to past infections where treat-
ment was interrupted. Nevertheless, our study showed a
potential benefit of screening and offering preventive
therapy for this specific vulnerable population. Preventing
the emergence of new index cases in this hard-to-reach
population that often lives in close quarters could sub-
stantially reduce expenses related to controlling an out-
break [38]. The high prevalence of LTBI suggests that
screening with an interferon-γ assay could be cost-effective
under conditions that promoted adherence to the end of
therapy for most patients [36]. However, the risk of devel-
oping tuberculosis is much higher for individuals with
positive intereron-γ results than those with a positive
tuberculosis skin test [39].
The acceptance rate for screening was high (81.4%). Using
nurse practitioners and trained primary physicians in
secure environments could help build the trust of this
hard-to-reach population. Maintaining confidentiality
could be essential to assure trust [40].
On the other hand, there are obstacles in ensuring that
patients follow their treatment to the end. Only five
patients out of eighteen with LTBI completed the preven-
tive therapy in our study. Ailinger et al [41] observed an
adherence prevalence of 72% for Latino patients that were
undocumented immigrants in Washington DC. A prior
study from our institution observed that the rate of adher-
ence was 76% in a group composed mainly of foreign
workers and refugees [42]. Therefore, adherence to treat-
ment may depend on the setting and the confidence the
patients have in the system (fear of denunciation and
rejection). Supervising [43] or monitoring [44] drug
administration, offering free access to care [45], using
models of explanation based on the patient's representa-
tion of his own health [46], and relying on trained nurse
practitioners for screening [47,48] could improve compli-
ance. Furthermore, compared to tuberculosis skin tests,
the introduction of interferon-γ assays has largely
improved the specificity of LTBI detection; thus, the
number of patients that would receive preventive treat-
ment without needing it can be reduced. This knowledge
might raise the motivation of healthcare workers in their
efforts to follow patients and help them adhere to the pro-
posed treatment.
Our study has several weaknesses. The small size of the
population sample led to a lack of precision in the results.
The absence of a non-migrant control group made it diffi-
cult to compare the prevalence of LTBI in migrants with
that of the local population; however, we considered it
safe to assume that the local population living in Switzer-
land had a much lower prevalence of LTBI than the study
population. The setting of our study could limit the gen-
eralisability of our results to rural migrants attending a
healthcare centre. Patients who do not attend a healthcare
centre could be younger and less deprived than those
included in the study. Our population could be more at
risk to have been in contact with tuberculosis. Our results
are therefore limited to quantifying the prevalence ofBMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34
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latent tuberculosis in a setting in which it is possible to
consider targeted screening and prevention programs to
take place. Finally, interferon-γ positivity may not equate
perfectly with latent TB infection. As such additionally
data using another interferon-γ or the tuberculosis skin
test would have been helpful.
Conclusion
Our study shows the benefit of using highly sensitive
assays for detecting LTBI on targeted populations at risk
that easily accept screening in appropriate health settings
by trained nurse practitioners and primary care physi-
cians. Nevertheless, methods for improving adherence to
Adherence to therapy from testing to the end of prophylactic therapies Figure 2
Adherence to therapy from testing to the end of prophylactic therapies. * Total number of participants with LTBI 
was expected to be 18. We assumed that the four patients that did not show up for further examination did not have active 
TB.
Positive T-Spot
n=24 (19.2%)
Complementary 
exams
n=16 
Started therapy
n=10 
TB
n=2 
(1.6%)
LTBI
n=14 
(11.2%)*
Hospitalised
n=2 
Ended therapy
n=5 
Did not have X-ray
• Already treated for TB/LTBI 4
• Did not show -up for exam 4
Surveillance
n=4 
Counter-indicated
n=4 BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34
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treatment are lacking. Our results demonstrate the high
prevalence of LTBI in migrants and emphasize the need
for developed countries to invest in programs that reduce
the transmission of tuberculosis worldwide; in particular,
the focus should be on undocumented migrants that fre-
quently come from countries with high incidence rates of
tuberculosis.
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virus.
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